Japanese drugmaker Takeda has announced earnings results for the first quarter of Japan’s fiscal year 2025, ending June 30.

Japanese drugmaker Eisai revealed that its in-house discovered tyrosine kinase inhibitor, Lenvima (lenvatinib mesylate), in combination with the anti-PD-1 antibody, pembrolizumab, and transarterial ...

US AI-focused start-up Formation Bio and IMIDomics, a precision medicine company focused on immune-mediated inflammatory diseases today announced that Formation Bio has licensed worldwide rights to ...

USA-based Madrigal Pharmaceuticals today announced that it has entered into an exclusive global license agreement with CSPC ...

LTZ Therapeutics, a Sino-American biotech focused on immunotherapy, has announced a strategic research collaboration with US ...

Germany’s Evotec today announced a non-binding agreement with Switzerland’s Sandoz regarding the potential sale of Just – ...

Shares of DURECT Corporation shot up 240% to $1.88 by close of trading Tuesday, after Canada’s Bausch Health agreed to ...

Swiss pharma company Idorsia today released encouraging first half 2025 financial results, sending its shares up 8.5% to 2.94 ...

US pharma giant Pfizer has criticized the recent inclusion of the company in the list of enterprises that should be denied ...

Apellis Pharmaceuticals (Nasdaq: APLS) has received clearance from the American medicines regulator for Empaveli (pegcetacoplan) as the first treatment to reduce proteinuria in patients aged 12 and ...

Artbio, a US biotech specializing in radiopharmaceuticals, has raised $132 million in a series B financing to move its lead ...

A major US trial has found that structured healthy lifestyle programs can slow memory loss in older adults, regardless of ...